Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT

Hepato-Gastroenterology

Volumn 58, Issue 109, 2011, Pages 1321-1327

  Park, Jae Jun ^a,b   Park, Jun Yong ^a,c   Kim, Do Young ^a,c   Park, Young Nyun ^a,c,d   Ahn, Sang Hoon ^a,c   Chon, Chae Yoon ^a,c   Han, Kwang Hyub ^a,c,d  

^a Yonsei University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Liver Cirrhosis Clinical Research Center   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Chronic hepatitis C; Liver stiffness measurement to platelet ratio index; Persistently normal alanine aminotransferase; Significant fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER STIFFNESS MEASUREMENT; MALE; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RIGIDITY; SPLEEN SIZE; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; ALANINE TRANSAMINASE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 83355172725     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11041     Document Type: Article

References (39)

1. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001; 345:41-52. (Pubitemid 32634271)
2. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A: Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137:961-964. (Pubitemid 35440242)
3. Alberti A: Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005; 42:266-274.
4. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al.: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27:868-872. (Pubitemid 28103567)
5. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al.: Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393-1398. (Pubitemid 27520001)
6. Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, et al.: Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 2006; 24:1133-1149. (Pubitemid 44427502)
7. Hui CK, Belaye T, Montegrande K, Wright TL: A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38:511-517. (Pubitemid 36399256)
8. Cividini A, Rebucci C, Silini E, Mondelli MU: Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology 2001; 121:1526-1527.
9. Puoti C, Bellis L, Martellino F, Guarisco R, Dell' Unto O, Durola L, et al.: Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. J Hepatol 2005; 43:534-535. (Pubitemid 41111437)
10. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, et al.: Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37:117-123. (Pubitemid 34713063)
11. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al.: Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36:973-977.
12. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171. (Pubitemid 38428955)
13. McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, et al.: Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22:615-633. (Pubitemid 46608388)
14. EASL: International Consensus Conference on Hepatitis C. J Hepatol 1999; 31:3-8.
15. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al.: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732. (Pubitemid 39575851)
16. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001; 344:495-500. (Pubitemid 32164902)
17. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32:477-481.
18. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al.: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1:523-525. (Pubitemid 16138427)
19. Bedossa P DD, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 1449-1457.
20. Colloredo G, Guido M, Sonzogni A, Leandro G: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239-244. (Pubitemid 36920560)
21. Afdhal NH, Nunes D: Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174. (Pubitemid 38917824)
22. Rockey DC, Bissell DM: Noninvasive measures of liver fibrosis. Hepatology 2006; 43:S113-120.
23. Han KH, Yoon KT: New diagnostic method for liver fibrosis and cirrhosis. Intervirology 2008; 51 Suppl 1:11-16.
24. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45:297-306. (Pubitemid 46374586)
25. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350. (Pubitemid 40439195)
26. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al.: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54. (Pubitemid 40066382)
27. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, et al.: Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42:838-845. (Pubitemid 41401121)
28. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al.: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44:686-693.
29. Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, et al.: Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006; 39:339-343.
30. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al.: Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006; 26:1087-1094. (Pubitemid 44541750)
31. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINTVIR, and DOSVIRC groups. Lancet 1997; 349:825-832. (Pubitemid 27129209)
32. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997; 26:2-10S.
33. Castera L, Bail BL, Roudot-Thoraval F, Bernard PH, Foucher J, Merrouche W, et al.: Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009; 50:59-68.
34. Shaheen AA, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102:2589-2600. (Pubitemid 47631778)
35. Cioni G, Tincani E, D'Alimonte P, Cristani A, Ventura P, Abbati G, et al.: Relevance of reduced portal flow velocity, low platelet count and enlarged spleen diameter in the non-invasive diagnosis of compensated liver cirrhosis. Eur J Med 1993; 2:408-410. (Pubitemid 23267317)
36. Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, et al.: Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 2006; 43:374-375; author reply 375-376.
37. Sebastiani G VA, Guido M, Alberti A: Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15:212-218. (Pubitemid 351143742)
38. Puoti C, Guido M, Mangia A, Persico M, Prati D: Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35:362-369. (Pubitemid 41110865)
39. Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G.: Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004; 36:646-654. (Pubitemid 41115431)